Statistical evaluation of thyroid tumors: a 10-year retrospective study

Abstract

Objective: Thyroid tumors are among the most common head and neck malignancies. In this study, thyroid cancer cases diagnosed in our department were examined in the light of the literature. Material and Method: All thyroid cancer patients operated between 2010 and 2020 were included in the study. The clinicopathological features of the cases were analyzed statistically. Results: Thyroid tumors were seen 4 times more in women than men. 48.7% of our patients were in the 40-59 age group, and 32.8% were in the 20-39 age group. Localized tumor was present in 80.6% of the cases, and metastatic tumor was present in 18.4%. Thyroid cancers were found with the highest rate in the 40-49 age range in women and the highest rate in the 50-59 age range in men. Localized tumor stage was determined with the highest rate with 65.3%. Also, localized tumor stages were detected in 69.8% of women and 54.7% of men. When the distribution of thyroid cancers by gender was investigated, a statistically significant difference was found in terms of stage (p<0.001), age (p<0.001), and lypmh node status (p<0.05). Conclusion: Our findings show that the early diagnosis of patients with thyroid tumors has increased considerably in our country. Also, our statistical results were similar to the literature and this shows that our country is successful in the management of thyroid tumors.

Keywords

• Thyroid tumors
• prognostic parameters
• head and neck tumors

Tiroid tümörlerinin istatistiksel olarak incelenmesi: 10 yıllık retrospektif bir çalışma

Abstract

Amaç: Tiroid tümörleri baş-boyun maligniteleri arasında en sık görülen tümörlerdendir. Bu çalışmada bölümümüzde tanı almış tiroid kanseri olguları literatür bilgileri eşliğinde incelendi. Gereç ve Yöntem: 2010-2020 yılları arasında opere edilmiş tüm tiroid kanser hastaları çalışmaya dahil edildi. Olguların klinikopatolojik özellikleri istatistiksel olarak analiz edildi. Bulgular: Tiroid tümörleri kadınlarda erkeklere göre 4 kat fazla görüldü. Hastalarımızın %48,7’i 40-59 yaş grubunda, %32,8’si 20-39 yaş grubunda yer almakta idi. Olguların %80,6’sında lokalize tümör, %18,4’ünde ise metastatik tümör mevcut idi. Tiroid kanserleri kadınlarda 40-49 yaş aralığında en yüksek oranda; erkeklerde ise 50-59 yaş aralığında en yüksek oranda saptandı. Lokalize tümör evresi %65,3 ile en yüksek oranda tespit edildi. Ayrıca kadınlara %69,8 erkeklerde ise %54,7 oranlarında lokalize tümör evresi saptandı. Tiroid kanserlerinin cinsiyet açısından dağılımı araştırıldığında, evre (p<0,001), yaş (p<0,0001) ve lenf nodu durumu (p<0,05) açısından istatistiksel olarak anlamlı fark görüldü. Sonuç: Bulgularımız ülkemizde tiroid tümörlü olguların erken teşhisinin oldukça arttığını göstermektedir. Ayrıca istatistiksel sonuçlarımız literatür ile benzerdi ve bu durum ülkemizin tiroid tümörlerinin yönetiminde başarılı olduğunu göstermektedir.

Keywords

• prognostik parametreler
• Tiroid tümörleri
• baş-boyun tümörleri

References

1. Lamartina L, Grani G, Durante C, Filetti S, Cooper DS. Screening for differentiated thyroid cancer in selected populations. Lancet Diabetes Endocrinol 2020; 8: 81-8.
2. Singh Ospina N, Iñiguez-Ariza NM, Castro MR. Thyroid nodules: diagnostic evaluation based on thyroid cancer risk assessment. BMJ 2020; 368: 16670.
3. Roman BR, Morris LG, Davies L. The thyroid cancer epidemic, 2017 perspective. Curr Opin Endocrinol Diabetes Obes 2017; 24: 332-6.
4. Lamartina L, Grani G, Durante C, Borget I, Filetti S, Schlumberger M. Follow-up of differentiated thyroid cancer - what should (and what should not) be done. Nat Rev Endocrinol 2018; 14: 538-51.
5. Bibbins-Domingo K, Grossman DC, Curry SJ, et. al. Screening for thyroid cancer: US Preventive Services Task Force recommendation statement. JAMA 2017; 317: 1882-7.
6. Valderrabano P, Khazai L, Thompson ZJ, et al. Cancer Risk Stratification of Indeterminate Thyroid Nodules: A Cytological Approach. Thyroid 2017; 27: 1277-4.
7. Mitro SD, Rozek LS, Vatanasapt P, et al. Iodine deficiency and thyroid cancer trends in three regions of Thailand, 1990-2009. Cancer Epidemiol 2016; 43: 92-9.
8. Roman BR, Morris LG, Davies L. The thyroid cancer epidemic, 2017 perspective. Curr Opin Endocrinol Diabetes Obes 2017; 24: 332-6.

9. Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and fifferentiated thyroid cancer. Thyroid 2016; 26: 1-133.
10. Carling T, Ocal IT, Udelsman R. Special variants of differentiated thyroid cancer: does it alter the extent of surgery versus well-differentiated thyroid cancer? World J Surg 2007; 31: 916-23.
11. Saravana-Bawan B, Bajwa A, Paterson J, McMullen T. Active surveillance of low-risk papillary thyroid cancer: A meta-analysis. Surgery 2020; 167: 46-55.
12. Perri F, Giordano A, Pisconti S, et al. Thyroid cancer management: from a suspicious nodule to targeted therapy. Anticancer Drugs. 2018; 29: 483-90.
13. Elisei R, Pinchera A. Advances in the follow-up of differentiated or medullary thyroid cancer. Nat Rev Endocrinol 2012; 8: 466-75.
14. Gweon HM, Son EJ, Kim JA, Youk JH. Predictive factors for active surveillance of subcentimeter thyroid nodules with highly suspicious US features. Ann Surg Oncol 2017; 24: 1540-45.
15. Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: a review of active surveillance trials. Eur J Surg Oncol 2018; 44: 307-15.
16. Sanabria A. Active surveillance in thyroid microcarcinoma in a Latin-American cohort. JAMA Otolaryngol Head Neck Surg 2018; 144: 947-8.